01 June 2010
Low expression of Sp100 in laryngeal cancer: Correlation with cell differentiation
Wei LiBCDE, Chao ShangG, Chao GuanB, Yong ZhangB, Kailai SunF, Weineng FuAMed Sci Monit 2010; 16(6): BR174-178 :: ID: 880605
Abstract
Background: Sp100 is a permanent ProMyelocytic Leukaemian nuclear bodies (PML NB)-associated protein, and has been reported to participate in the regulation of transcriptional activity, apoptosis and other cellular biological processes. The aim of the present study was to explore the expression of Sp100 and its potential clinical implications in laryngeal cancer.
Material/Methods: The mRNA and protein levels of Sp100 in 96 laryngeal cancer samples and paired normal epithelium were examined by RT-PCR, Western blot and immuno-histochemical staining. The correlation of Sp100 expression with clinicopathological features of these patients was assessed by Chi-squared test.
Results: The coherent low Sp100 expression of both transcriptional and translational levels were confirmed in the malignant tissues compared to the normal mucosa, and the expression was down-regulated among the well-, moderately- and poorly-differentiated cancer cells accordingly. Moreover, immuno-histochemical staining demonstrated that Sp100 showed a predominantly nuclear pattern in well-differentiated cancer cells, and diffuse cellular distribution in cytoplasm in poorly-differentiated cancer cells. Besides histological type of cancer cells, other clinicopathological characteristics, including age, sex, T classification, lymph node metastasis, distant metastasis and clinical stage, showed no significant correlation with Sp100 low expression.
Conclusions: Our finding provides an important clue to further understanding the role of Sp100 in the initiation and progression of tumorgenesis.
Keywords: Laryngeal Neoplasms - metabolism, Immunohistochemistry - methods, Carcinoma, Squamous Cell - metabolism, Blotting, Western, Autoantigens - biosynthesis, Antigens, Nuclear - biosynthesis, Reverse Transcriptase Polymerase Chain Reaction
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952